A point-of-care diagnostic platform that detects ultra-low concentrations of disease biomarkers through a micro bubbling digital assay. This robust platform has been validated through their ultrasensitive and low-cost COVID antigen test. Furthermore, this accurate at-home testing has broad potential in other areas where rapid, convenient, and ultra-sensitive biomarker detection is most vital, especially for cardiovascular conditions. Mainly as it improves patient enrollment and retention in longer-term trials

I-Corps Team Members:

Skip to content